

# Are needle and syringe programmes associated with a reduction in HIV risk among people who inject drugs: a systematic review and meta-analysis

International Journal of Epidemiology

43, 235-248

DOI: [10.1093/ije/dyt243](https://doi.org/10.1093/ije/dyt243)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Controlling HIV among people who inject drugs in Eastern Europe and Central Asia: Insights from modelling. International Journal of Drug Policy, 2014, 25, 1163-1173.	3.3	37
2	Shared subjects, divergent epistemologies: Sociology, social work, and social problems scholarship. Qualitative Social Work, 2014, 13, 757-765.	1.4	4
3	Addressing the HIV/AIDS Epidemic Among Puerto Rican People Who Inject Drugs: The Need for a Multiregion Approach. American Journal of Public Health, 2014, 104, 2030-2036.	2.7	19
4	HIV infection. Nature Reviews Disease Primers, 2015, 1, 15035.	30.5	340
5	Consequences of a restrictive syringe exchange policy on utilisation patterns of a syringe exchange program in <scp>B</scp>altimore, <scp>M</scp>aryland: Implications for <scp>HIV</scp> risk. Drug and Alcohol Review, 2015, 34, 637-644.	2.1	19
6	Correlates of Opioid Use in Adults With Self-Reported Drug Use Recruited From Public Safety-Net Primary Care Clinics. Journal of Addiction Medicine, 2015, 9, 417-426.	2.6	11
7	Estimating the Cost-Effectiveness of HIV Prevention Programmes in Vietnam, 2006-2010: A Modelling Study. PLoS ONE, 2015, 10, e0133171.	2.5	13
8	Global policy and access to new hepatitis C therapies for people who inject drugs. International Journal of Drug Policy, 2015, 26, 1064-1071.	3.3	14
9	The Role of Mental Health Services in Addressing HIV Infection Among Women With Serious Mental Illness. Psychiatric Services, 2015, 66, 966-974.	2.0	10
10	Trends and characteristics of heroin overdoses in Wisconsin, 2003â€“2012. Drug and Alcohol Dependence, 2015, 152, 177-184.	3.2	33
11	Novel Interventions to Prevent HIV and HCV Among Persons Who Inject Drugs. Current HIV/AIDS Reports, 2015, 12, 145-163.	3.1	18
12	Editorial Commentary:The Impact of Opiate Substitution Therapy and Highly Active Antiretroviral Therapy on Mortality Risk Among People Who Inject Drugs. Clinical Infectious Diseases, 2015, 61, 1166-1168.	5.8	4
13	HIV prevention and treatment strategies can help address the overdose crisis. Preventive Medicine, 2015, 80, 37-40.	3.4	4
14	Police, Law Enforcement and HIV. Journal of the International AIDS Society, 2016, 19, 21260.	3.0	0
15	Preâ€“incarceration police harassment, drug addiction and HIV risk behaviours among prisoners in Kyrgyzstan and Azerbaijan: results from a nationally representative crossâ€“sectional study. Journal of the International AIDS Society, 2016, 19, 20880.	3.0	21
16	Investing in People Who Inject Drugs: A PrEPonderance of Opportunities. Annals of Internal Medicine, 2016, 165, 63.	3.9	6
17	Psychoactive substances: Position statement on harm reduction. South African Medical Journal, 2016, 106, 836.	0.6	2
18	Linkage to Care for Suburban Heroin Users with Hepatitis C Virus Infection, New Jersey, USA. Emerging Infectious Diseases, 2016, 22, 907-909.	4.3	18

#	ARTICLE	IF	CITATIONS
19	Syringe Stockpiling by Persons Who Inject Drugs: An Evaluation of Current Measures for Needle and Syringe Program Coverage. <i>American Journal of Epidemiology</i> , 2016, 183, 852-860.	3.4	20
20	Overlapping substance using high-risk groups and infectious diseases: how dynamic modelling can evaluate risk and target HIV prevention. <i>Addiction</i> , 2016, 111, 1512-1515.	3.3	7
21	Innovative community-based educational face-to-face intervention to reduce HIV, hepatitis C virus and other blood-borne infectious risks in difficult-to-reach people who inject drugs: results from the ANRS-AERLI intervention study. <i>Addiction</i> , 2016, 111, 94-106.	3.3	42
22	HIV seroconversion and risk factors among drug users receiving methadone maintenance treatment in China: A qualitative study. <i>Drug and Alcohol Dependence</i> , 2016, 167, 169-174.	3.2	4
23	Harm reduction and e-cigarettes: Distorting the approach. <i>Journal of Public Health Policy</i> , 2016, 37, 403-410.	2.0	8
24	HIV Infection Linked to Injection Use of Oxymorphone in Indiana, 2014-2015. <i>New England Journal of Medicine</i> , 2016, 375, 229-239.	27.0	493
25	A needle in the haystack – the dire straits of needle exchange in Hungary. <i>BMC Public Health</i> , 2016, 16, 157.	2.9	15
26	Overview of HIV molecular epidemiology among people who inject drugs in Europe and Asia. <i>Infection, Genetics and Evolution</i> , 2016, 46, 256-268.	2.3	26
27	HIV Risk Behavior Among Methamphetamine Users Entering Substance Abuse Treatment in Cape Town, South Africa. <i>AIDS and Behavior</i> , 2016, 20, 2387-2397.	2.7	7
28	HIV Prevention 2020: a framework for delivery and a call for action. <i>Lancet HIV</i> , 2016, 3, e323-e332.	4.7	54
29	Public health and international drug policy. <i>Lancet, The</i> , 2016, 387, 1427-1480.	13.7	460
30	Drug Treatment Policy in the Criminal Justice System: A Scoping Literature Review. <i>American Journal of Criminal Justice</i> , 2016, 41, 3-13.	2.0	5
31	Economic Evaluation of Community-Based HIV Prevention Programs in Ontario: Evidence of Effectiveness in Reducing HIV Infections and Health Care Costs. <i>AIDS and Behavior</i> , 2016, 20, 1143-1156.	2.7	8
32	Getting the balance right: Scaling-up treatment and prevention. <i>Global Public Health</i> , 2017, 12, 483-497.	2.0	4
33	Death from liver disease in a cohort of injecting opioid users in a Swedish city in relation to registration for opioid substitution therapy. <i>Drug and Alcohol Review</i> , 2017, 36, 424-431.	2.1	8
34	It Goes on Everywhere: Injection Drug Use in Canadian Federal Prisons. <i>Substance Use and Misuse</i> , 2017, 52, 884-891.	1.4	22
35	Harm reduction as a strategy for supporting people who self-harm on mental health wards: the views and experiences of practitioners. <i>Journal of Affective Disorders</i> , 2017, 214, 67-73.	4.1	27
36	Barriers to Access to Sterile Syringes as Perceived by Pharmacists and Injecting Drug Users: Implications for Harm Reduction in Lebanon. <i>Substance Use and Misuse</i> , 2017, 52, 1420-1428.	1.4	8

#	ARTICLE	IF	CITATIONS
37	Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program. <i>Infectious Diseases</i> , 2017, 49, 728-736.	2.8	30
38	New developments and opportunities for preventing hepatitis C virus (HCV) among people who use and inject drugs-announcing an <i>Addiction</i> series. <i>Addiction</i> , 2017, 112, 1126-1127.	3.3	2
39	Health and Public Policy to Facilitate Effective Prevention and Treatment of Substance Use Disorders Involving Illicit and Prescription Drugs: An American College of Physicians Position Paper. <i>Annals of Internal Medicine</i> , 2017, 166, 733.	3.9	58
40	Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996â€“2013: a modelling study. <i>Lancet HIV</i> , 2017, 4, e303-e310.	4.7	31
41	Elimination of HCV as a public health concern among people who inject drugs by 2030 â€“ What will it take to get there?. <i>Journal of the International AIDS Society</i> , 2017, 20, 22146.	3.0	126
42	A Controlled Trial to Reduce the Risk of Human Nipah Virus Exposure in Bangladesh. <i>EcoHealth</i> , 2017, 14, 501-517.	2.0	16
43	Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. <i>The Cochrane Library</i> , 2017, 2017, CD012021.	2.8	158
44	Public Health and Public Order Outcomes Associated with Supervised Drug Consumption Facilities: a Systematic Review. <i>Current HIV/AIDS Reports</i> , 2017, 14, 161-183.	3.1	150
45	Pence, Putin, Mbeki and Their HIV/AIDS-Related Crimes Against Humanity: Call for Social Justice and Behavioral Science Advocacy. <i>AIDS and Behavior</i> , 2017, 21, 963-967.	2.7	11
46	Animal house: University risk environments and the regulation of studentsâ€™ alcohol use. <i>International Journal of Drug Policy</i> , 2017, 47, 18-25.	3.3	21
47	Decreased Odds of Injection Risk Behavior Associated With Direct Versus Indirect Use of Syringe Exchange: Evidence From Two California Cities. <i>Substance Use and Misuse</i> , 2017, 52, 1145-1153.	1.4	14
48	Awareness of pre-exposure prophylaxis (PrEP) among women who inject drugs in NYC: the importance of networks and syringe exchange programs for HIV prevention. <i>Harm Reduction Journal</i> , 2017, 14, 40.	3.2	95
49	Effectiveness of needle and syringe Programmes in people who inject drugs â€“ An overview of systematic reviews. <i>BMC Public Health</i> , 2017, 17, 309.	2.9	200
50	Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study. <i>Harm Reduction Journal</i> , 2017, 14, 19.	3.2	33
51	The acceptability and feasibility of a brief psychosocial intervention to reduce blood-borne virus risk behaviours among people who inject drugs: a randomised control feasibility trial of a psychosocial intervention (the PROTECT study) versus treatment as usual. <i>Harm Reduction Journal</i> , 2017, 14, 14.	3.2	4
52	Needle exchange programs for the prevention of hepatitis C virus infection in people who inject drugs: a systematic review with meta-analysis. <i>Harm Reduction Journal</i> , 2017, 14, 25.	3.2	35
53	Students as effective harm reductionists and needle exchange organizers. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2017, 12, 15.	2.2	10
54	Insights on Prison Needle and Syringe Programs: Research With Former Prisoners in Canada. <i>Prison Journal</i> , 2017, 97, 628-643.	0.7	7

#	ARTICLE	IF	CITATIONS
55	Drug Use Is Associated With Purulent Skin and Soft Tissue Infections in a Large Urban Jail: 2011–2015. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx135.	0.9	0
56	Enrolment and retention of people who inject drugs in the Needle & Syringe Exchange Programme in Malaysia. <i>Public Health Action</i> , 2017, 7, 155-160.	1.2	4
57	Reduction of Injection-Related Risk Behaviors After Emergency Implementation of a Syringe Services Program During an HIV Outbreak. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 77, 373-382.	2.1	35
58	Understanding and Improving the Health of People Who Experience Incarceration: An Overview and Synthesis. <i>Epidemiologic Reviews</i> , 2018, 40, 4-11.	3.5	104
59	Increasing methamphetamine injection among non-MSM who inject drugs in King County, Washington. <i>Drug and Alcohol Dependence</i> , 2018, 182, 86-92.	3.2	74
60	Epidemics of HIV, HCV and syphilis infection among synthetic drugs only users, heroin-only users and poly-drug users in Southwest China. <i>Scientific Reports</i> , 2018, 8, 6615.	3.3	15
61	Mobilising a global response to hepatitis: Lessons learned from the HIV movement. <i>Global Public Health</i> , 2018, 13, 473-488.	2.0	3
62	Scaling up HCV prevention and treatment interventions in rural United States—model projections for tackling an increasing epidemic. <i>Addiction</i> , 2018, 113, 173-182.	3.3	71
63	Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. <i>Addiction</i> , 2018, 113, 545-563.	3.3	242
64	Dynamics and control of infections on social networks of population types. <i>Epidemics</i> , 2018, 23, 11-18.	3.0	2
65	What works in inclusion health: overview of effective interventions for marginalised and excluded populations. <i>Lancet, The</i> , 2018, 391, 266-280.	13.7	245
66	Factors associated with public injection and nonfatal overdose among people who inject drugs in street-based settings. <i>Drugs: Education, Prevention and Policy</i> , 2018, 25, 38-46.	1.3	6
67	The Politics of Harm Reduction: Comparing the Historical Development of Needle Exchange Policy in Canada and the UK between 1985 and 1995. <i>social history of alcohol and drugs, The</i> , 2018, 32, 81-103.	0.2	3
68	PRO: Needle Exchange Programs Should Be Instituted to Reduce Hepatitis C Virus Transmission. <i>Clinical Liver Disease</i> , 2018, 12, 170-172.	2.1	6
69	Contraceptive utilization among new exotic dancers: a cross-sectional study. <i>Harm Reduction Journal</i> , 2018, 15, 56.	3.2	1
70	Regional differences between people who inject drugs in an HIV prevention trial integrating treatment and prevention (HPTN 074): a baseline analysis. <i>Journal of the International AIDS Society</i> , 2018, 21, e25195.	3.0	13
71	Recommendations for the Appropriate Structure, Communication, and Investigation of Tobacco Harm Reduction Claims. An Official American Thoracic Society Policy Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, e90-e105.	5.6	14
72	Psychiatric and Substance Use Comorbidity in Treatment-Seeking Injection Opioid Users Referred From Syringe Exchange. <i>Journal of Dual Diagnosis</i> , 2018, 14, 193-200.	1.2	21

#	ARTICLE	IF	CITATIONS
73	Effect of opioid-substitution therapy and mental health counseling on HIV risk among hepatitis C-infected individuals. <i>Clinical Epidemiology</i> , 2018, Volume 10, 1127-1145.	3.0	7
74	Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 1397-1409.	9.1	147
75	Building the Case for Localized Approaches to HIV: Structural Conditions and Health System Capacity to Address the HIV/AIDS Epidemic in Six US Cities. <i>AIDS and Behavior</i> , 2018, 22, 3071-3082.	2.7	31
76	Treatment initiation strategies for syringe exchange referrals to methadone maintenance: A randomized clinical trial. <i>Drug and Alcohol Dependence</i> , 2018, 187, 343-350.	3.2	17
77	HIV/HCV Co-infection: Burden of Disease and Care Strategies in Appalachia. <i>Current HIV/AIDS Reports</i> , 2018, 15, 308-314.	3.1	5
78	Potential impact of implementing and scaling up harm reduction and antiretroviral therapy on HIV prevalence and mortality and overdose deaths among people who inject drugs in two Russian cities: a modelling study. <i>Lancet HIV</i> , the, 2018, 5, e578-e587.	4.7	29
79	Impact of an educational intervention on risks associated with drug injection, and on psychosocial factors (PSF) involved in initiating and maintaining new health behaviors over time. <i>Addictive Behaviors</i> , 2018, 87, 222-230.	3.0	3
80	Scoping out the literature on mobile needle and syringe programsâ€”review of service delivery and client characteristics, operation, utilization, referrals, and impact. <i>Harm Reduction Journal</i> , 2018, 15, 6.	3.2	37
81	Pharmacistsâ€™ role in harm reduction: a survey assessment of Kentucky community pharmacistsâ€™ willingness to participate in syringe/needle exchange. <i>Harm Reduction Journal</i> , 2018, 15, 4.	3.2	23
82	The discordance between evidence and health policy in the United States: the science of translational research and the critical role of diverse stakeholders. <i>Health Research Policy and Systems</i> , 2018, 16, 81.	2.8	21
83	<i>Drug Policy and the Public Good</i>: a summary of the second edition. <i>Addiction</i> , 2019, 114, 1941-1950.	3.3	7
84	Sexual risk behaviors and STDs among persons who inject drugs: A national study. <i>Preventive Medicine</i> , 2019, 126, 105779.	3.4	42
85	How Clinicians Caring for Youth Can Address the Opioid-Related Overdose Crisis. <i>Journal of Adolescent Health</i> , 2019, 65, 177-180.	2.5	22
86	Improving HIV service delivery for people who inject drugs in Kazakhstan: study protocol for the Bridge stepped-wedge trial. <i>Implementation Science</i> , 2019, 14, 62.	6.9	6
87	Global patterns of opioid use and dependence: harms to populations, interventions, and future action. <i>Lancet</i> , The, 2019, 394, 1560-1579.	13.7	404
88	Responding to global stimulant use: challenges and opportunities. <i>Lancet</i> , The, 2019, 394, 1652-1667.	13.7	169
89	Changes in Reported Injection Behaviors Following the Public Health Response to an HIV Outbreak Among People Who Inject Drugs: Indiana, 2016. <i>AIDS and Behavior</i> , 2019, 23, 3257-3266.	2.7	11
90	Paraphernalia Laws, Criminalizing Possession and Distribution of Items Used to Consume Illicit Drugs, and Injection-Related Harm. <i>American Journal of Public Health</i> , 2019, 109, 1564-1567.	2.7	24

#	ARTICLE	IF	CITATIONS
91	Distributive Syringe Sharing and Use of Syringe Services Programs (SSPs) Among Persons Who Inject Drugs. <i>AIDS and Behavior</i> , 2019, 23, 3306-3314.	2.7	11
92	The characteristics and patterns of utilization of healthcare services among Omanis with substance use disorders attending therapy for cessation. <i>PLoS ONE</i> , 2019, 14, e0210532.	2.5	14
93	Evaluating the cost-effectiveness of existing needle and syringe programmes in preventing hepatitis C transmission in people who inject drugs. <i>Addiction</i> , 2019, 114, 560-570.	3.3	29
94	The Moral Foundations of Needle Exchange Attitudes. <i>Social Cognition</i> , 2019, 37, 229-246.	0.9	16
95	Outcome evaluation of a "common factors" approach to develop culturally tailored HIV prevention interventions for people who inject drugs. <i>Drug and Alcohol Dependence</i> , 2019, 199, 18-26.	3.2	2
96	Anticipating the spread of HIV: the past is prologue. <i>Annals of Epidemiology</i> , 2019, 34, 6-7.	1.9	0
97	Lessons from Scott County "Progress or Paralysis on Harm Reduction?". <i>New England Journal of Medicine</i> , 2019, 380, 1988-1990.	27.0	23
98	Perceived acceptability of and willingness to use syringe vending machines: results of a cross-sectional survey of out-of-service people who inject drugs in Tbilisi, Georgia. <i>Harm Reduction Journal</i> , 2019, 16, 21.	3.2	15
99	Attitudes towards people living with HIV and people who inject drugs: A mixed method study of stigmas within harm reduction programs in Kazakhstan. <i>International Journal of Drug Policy</i> , 2019, 68, 27-36.	3.3	13
100	Increased HIV diagnoses in West Virginia counties highly vulnerable to rapid HIV dissemination through injection drug use: a cautionary tale. <i>Annals of Epidemiology</i> , 2019, 34, 12-17.	1.9	31
101	Evaluating the impact of global fund withdrawal on needle and syringe provision, cost and use among people who inject drugs in Tijuana, Mexico: a costing analysis. <i>BMJ Open</i> , 2019, 9, e026298.	1.9	13
102	HIV and Substance Use Disorder. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 835-855.	5.1	12
103	Sharing of Injection Drug Preparation Equipment Is Associated With HIV Infection: A Cross-sectional Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, e99-e103.	2.1	32
104	Elimination of HIV transmission through novel and established prevention strategies among people who inject drugs. <i>Lancet HIV</i> , 2019, 6, e128-e136.	4.7	27
105	Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 135-184.	8.1	370
106	Primary versus secondary prevention messages: College students' perceptions of effectiveness by marijuana user status. <i>Journal of American College Health</i> , 2019, 67, 743-752.	1.5	3
107	Factors Associated with Awareness of Pre-exposure Prophylaxis for HIV Among Persons Who Inject Drugs in Philadelphia: National HIV Behavioral Surveillance, 2015. <i>AIDS and Behavior</i> , 2019, 23, 1833-1840.	2.7	34
108	Public Opinion and Public Policy: Heroin and Other Opioids. <i>Criminal Justice Policy Review</i> , 2019, 30, 1163-1185.	1.0	9



#	ARTICLE	IF	CITATIONS
109	Rapid Identification and Investigation of an HIV Risk Network Among People Who Inject Drugs â€”Miami, FL, 2018. <i>AIDS and Behavior</i> , 2020, 24, 246-256.	2.7	37
110	Prevalence of Injecting Drug Use and Coverage of Interventions to Prevent HIV and Hepatitis C Virus Infection Among People Who Inject Drugs in Canada. <i>American Journal of Public Health</i> , 2020, 110, 45-50.	2.7	44
111	HIV prevalence among people who inject drugs (PWID) and related factors in Iran: a systematic review, meta-analysis and trend analysis. <i>Addiction</i> , 2020, 115, 605-622.	3.3	34
112	Online HIV information seeking and pre-exposure prophylaxis awareness among people who use drugs. <i>Journal of Substance Abuse Treatment</i> , 2020, 111, 16-22.	2.8	5
113	Opioid use disorder. <i>Nature Reviews Disease Primers</i> , 2020, 6, 3.	30.5	278
114	Opioid-related deaths in Europe: Strategies for a comprehensive approach to address a major public health concern. <i>International Journal of Drug Policy</i> , 2020, 76, 102616.	3.3	58
115	The impact of localized implementation: determining the cost-effectiveness of HIV prevention and care interventions across six United States cities. <i>Aids</i> , 2020, 34, 447-458.	2.2	36
116	Syringe access and health harms: Characterizing â€œlandscapes of antagonismâ€”in California's Central Valley. <i>International Journal of Drug Policy</i> , 2020, 75, 102594.	3.3	13
117	Making the Case for Syringe Services Programs. <i>Public Health Reports</i> , 2020, 135, 10S-12S.	2.5	17
118	Roles for Pharmacists in the â€œEnding the HIV Epidemic: A Plan for Americaâ€”Initiative. <i>Public Health Reports</i> , 2020, 135, 547-554.	2.5	23
119	Trends in Morbidity, Mortality, and Cost of Hospitalizations Associated With Infectious Disease Sequelae of the Opioid Epidemic. <i>Journal of Infectious Diseases</i> , 2020, 222, S451-S457.	4.0	14
120	Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?. <i>Clinical Infectious Diseases</i> , 2020, 71, 2905-2916.	5.8	16
121	Human Immunodeficiency Virus Prevention for People Who Use Drugs: Overview of Reviews and the ICOS of PICOS. <i>Journal of Infectious Diseases</i> , 2020, 222, S278-S300.	4.0	8
122	Harm Reduction Coverage and Hepatitis C Incidence: Findings From a Cohort of People Who Inject Drugs. <i>American Journal of Preventive Medicine</i> , 2020, 58, 845-853.	3.0	7
123	Estimating the contribution of stimulant injection to HIV and HCV epidemics among people who inject drugs and implications for harm reduction: A modeling analysis. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108135.	3.2	20
124	Modelling integrated antiretroviral treatment and harm reduction services on HIV and overdose among people who inject drugs in Tijuana, Mexico. <i>Journal of the International AIDS Society</i> , 2020, 23, e25493.	3.0	11
125	Impact of routine opt-out HIV/HCV screening on testing uptake at a syringe services program: An interrupted time series analysis. <i>International Journal of Drug Policy</i> , 2020, 84, 102875.	3.3	12
126	Risky injection practices and HCV awareness in Chiang Mai Province, Thailand: a respondent-driven sampling study of people who inject drugs. <i>BMC Public Health</i> , 2020, 20, 1450.	2.9	1



#	ARTICLE	IF	CITATIONS
127	Syringe Service Program Utilization, Barriers, and Preferences for Design in Rural Appalachia: Differences between Men and Women Who Inject Drugs. <i>Substance Use and Misuse</i> , 2020, 55, 2268-2277.	1.4	21
128	Preventing HIV outbreaks among people who inject drugs in the United States: plus Ãa change, plus Ãa mÃme chose. <i>Aids</i> , 2020, 34, 1997-2005.	2.2	18
129	The Impact of Syringe Services Program Policy on Risk Behaviors Among Persons Who Inject Drugs in 3 US Cities, 2005-2015. <i>Public Health Reports</i> , 2020, 135, 138S-148S.	2.5	8
130	Health programmes and services addressing the prevention and management of infectious diseases in persons who inject drugs in Canada: a systematic integrative review protocol. <i>BMJ Open</i> , 2020, 10, e035188.	1.9	4
131	Understanding the Intersection of Behavioral Risk and Social Determinants of Health and the Impact on an Outbreak of Human Immunodeficiency Virus Among Persons Who Inject Drugs in Philadelphia. <i>Journal of Infectious Diseases</i> , 2020, 222, S250-S258.	4.0	18
132	Ending the HIV Epidemic Among Persons Who Inject Drugs: A Cost-Effectiveness Analysis in Six US Cities. <i>Journal of Infectious Diseases</i> , 2020, 222, S301-S311.	4.0	4
133	State Laws Governing Syringe Services Programs and Participant Syringe Possession, 2014-2019. <i>Public Health Reports</i> , 2020, 135, 128S-137S.	2.5	41
134	Opioid Policy Changes During the COVID-19 Pandemic - and Beyond. <i>Journal of Addiction Medicine</i> , 2020, 14, e4-e5.	2.6	68
135	Preventing HIV Outbreaks in Local Communities Among People Who Inject Drugs. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1325-1328.	3.0	0
136	Sex differences in the multilevel determinants of injection risk behaviours among people who inject drugs in Tijuana, Mexico. <i>Drug and Alcohol Review</i> , 2020, 39, 898-907.	2.1	2
137	Attributes of HIV infection over decades (1982â2018): A systematic review and metaâanalysis. <i>Transboundary and Emerging Diseases</i> , 2020, 67, 2372-2388.	3.0	21
138	Management of Opioid Use Disorder in the Emergency Department: A White Paper Prepared for the American Academy of Emergency Medicine. <i>Journal of Emergency Medicine</i> , 2020, 58, 522-546.	0.7	30
139	Needle exchange effectiveness in the midst of multiple injection-related epidemics: commentary on KÃrberg etÃal.. <i>Infectious Diseases</i> , 2020, 52, 347-349.	2.8	1
140	Substance use patterns and health profiles among US adults who use opioids, methamphetamine, or both, 2015-2018. <i>Drug and Alcohol Dependence</i> , 2020, 214, 108162.	3.2	58
141	Ranking evidence in substance use and addiction. <i>International Journal of Drug Policy</i> , 2020, 83, 102840.	3.3	8
142	Factors associated with injecting-related risk behaviors among people who inject drugs: a systematic review and meta-analysis study. <i>Journal of Addictive Diseases</i> , 2020, 38, 420-437.	1.3	31
143	The role of syringe exchange programs and sexual identity in awareness of pre-exposure prophylaxis (PrEP) for male persons who inject drugs. <i>International Journal of Drug Policy</i> , 2020, 77, 102671.	3.3	27
144	Significant decrease in injection risk behaviours among participants in a needle exchange programme. <i>Infectious Diseases</i> , 2020, 52, 336-346.	2.8	27

#	ARTICLE	IF	CITATIONS
145	Injecting drug use among gay and bisexual men in New Zealand: Findings from national human immunodeficiency virus epidemiological and behavioural surveillance. Drug and Alcohol Review, 2020, 39, 365-374.	2.1	6
146	Global systematic review and ecological analysis of HIV in people who inject drugs: National population sizes and factors associated with HIV prevalence. International Journal of Drug Policy, 2020, 77, 102656.	3.3	20
147	HIV control programs reduce HIV incidence but not HCV incidence among people who inject drugs in HaiPhong, Vietnam. Scientific Reports, 2020, 10, 6999.	3.3	17
148	Is hepatitis C virus (HCV) elimination achievable among people who inject drugs in Tijuana, Mexico? A modeling analysis. International Journal of Drug Policy, 2021, 88, 102710.	3.3	7
149	Correlates of disparities in syringe return ratios: A cross-sectional study of a syringe services program in New York. Journal of Substance Abuse Treatment, 2021, 121, 108193.	2.8	3
150	Skin and Soft Tissue Infections in Persons Who Inject Drugs. Infectious Disease Clinics of North America, 2021, 35, 169-181.	5.1	21
151	Developing a community-supported risk reduction intervention for syringe exchange registrants and their drug-free family or friends: a pilot study. Journal of Addictive Diseases, 2021, 39, 248-256.	1.3	0
152	A Critical Review of the Social and Behavioral Contributions to the Overdose Epidemic. Annual Review of Public Health, 2021, 42, 95-114.	17.4	33
153	Optimal Allocation of Societal HIV Prevention Resources to Reduce HIV Incidence in the United States. American Journal of Public Health, 2021, 111, 150-158.	2.7	10
154	Implementing harm reduction in non-urban communities affected by opioids and polysubstance use: A qualitative study exploring challenges and mitigating strategies. International Journal of Drug Policy, 2021, 90, 103080.	3.3	37
155	Refusals After Prehospital Administration of Naloxone during the COVID-19 Pandemic. Prehospital Emergency Care, 2021, 25, 46-54.	1.8	14
156	Opioid use disorder and HIV. , 2021, , 51-75.		0
157	The case of Scott County: injection drug use and the HIV and hepatitis C virus outbreak. , 2021, , 11-24.		0
158	Progression and transmission of HIV (PATH 4.0)-A new agent-based evolving network simulation for modeling HIV transmission clusters. Mathematical Biosciences and Engineering, 2021, 18, 2150-2181.	1.9	7
159	Emergency Department Treatment of Opioid Use Disorder. , 2021, , 57-75.		0
160	Harm reduction program and hepatitis C prevalence in people who inject drugs (PWID) in Iran: an updated systematic review and cumulative meta-analysis. Harm Reduction Journal, 2021, 18, 12.	3.2	9
161	Modeling the impact of harm reduction for opioid use disorder on infectious disease prevention. , 2021, , 247-274.		0
162	Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 137-146.	0.9	4

#	ARTICLE	IF	CITATIONS
163	Reducing Risky Drug Use Behaviors by Enrolling Syringe Exchange Registrants in Methadone Maintenance. Substance Use and Misuse, 2021, 56, 546-551.	1.4	3
165	Cost-effectiveness of hepatitis C virus (HCV) elimination strategies among people who inject drugs (PWID) in Tijuana, Mexico. Addiction, 2021, 116, 2734-2745.	3.3	4
166	Primary HIV-1 infection in users of pre-exposure prophylaxis. Lancet HIV, 2021, 8, e166-e174.	4.7	23
167	Sustainable Harm Reduction Needle and Syringe Programs for People Who Inject Drugs: A Scoping Review of Their Implementation Qualities. Sustainability, 2021, 13, 2834.	3.2	4
168	The opioid crisis and HIV in the USA: deadly synergies. Lancet, 2021, 397, 1139-1150.	13.7	68
169	Barriers and Challenges to Making Referrals for Treatment and Services for Opioid Misuse in Family Planning Settings. Journal of Women's Health, 2021, , .	3.3	0
170	Syringe Coverage Among People Who Inject Drugs in West Virginia, USA. AIDS and Behavior, 2021, 25, 3377-3385.	2.7	7
171	Pharmacists' nonprescription syringe dispensing perceptions and behaviors: A three-state descriptive analysis. Drug and Alcohol Dependence, 2021, 221, 108597.	3.2	7
172	Guide for Future Directions for the Addiction and OUD Treatment Ecosystem. NAM Perspectives, 0, , .	2.9	2
173	A Syringe Service Program Within a Federal System. Journal of Addictions Nursing, 2021, 32, 152-158.	0.4	1
174	Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Public Health, 2021, 6, e309-e323.	10.0	99
175	Sexual-risk reduction following the referral of syringe exchange registrants to methadone maintenance: Impact of gender and drug use. Journal of Substance Abuse Treatment, 2021, 124, 108286.	2.8	2
176	Can hepatitis C elimination targets be sustained among people who inject drugs post-2030?. International Journal of Drug Policy, 2021, 96, 103343.	3.3	5
177	Factors that influence enrollment in syringe services programs in rural areas: a qualitative study among program clients in Appalachian Kentucky. Harm Reduction Journal, 2021, 18, 68.	3.2	15
178	Integrating Harm Reduction into Outpatient Opioid Use Disorder Treatment Settings. Journal of General Internal Medicine, 2021, 36, 3810-3819.	2.6	34
179	Municipal police support for harm reduction services in officer-led referrals of people who inject drugs in Tijuana, Mexico. Harm Reduction Journal, 2021, 18, 76.	3.2	6
180	Professional education to reduce provider stigma toward harm reduction and pharmacotherapy. Drugs: Education, Prevention and Policy, 2022, 29, 576-586.	1.3	14
181	Burden of Infective Endocarditis in Homeless Patients in the United States: A National Perspective. American Journal of the Medical Sciences, 2021, 362, 39-47.	1.1	4

#	ARTICLE	IF	CITATIONS
182	Acceptability of an mHealth App That Provides Harm Reduction Services Among People Who Inject Drugs: Survey Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e25428.	4.3	4
183	An intensive model of care for hepatitis C virus screening and treatment with direct-acting antivirals in people who inject drugs in Nairobi, Kenya: a model-based cost-effectiveness analysis. <i>Addiction</i> , 2022, 117, 411-424.	3.3	6
184	HIV screening and retention in care in people who use drugs in Madrid, Spain: a prospective study. <i>Infectious Diseases of Poverty</i> , 2021, 10, 111.	3.7	1
185	Low barrier perinatal psychiatric care for patients with substance use disorder: meeting patients across the perinatal continuum where they are. <i>International Review of Psychiatry</i> , 2021, 33, 543-552.	2.8	7
186	Willingness to use syringe service programs and safe consumption sites among methadone patients with histories of injection drug use in a small Midwest community. <i>Addiction Research and Theory</i> , 2022, 30, 162-168.	1.9	3
187	“We’re actually more of a likely ally than an unlikely ally” relationships between syringe services programs and law enforcement. <i>Harm Reduction Journal</i> , 2021, 18, 81.	3.2	1
188	Factors that Influence Perception of HIV Risk and Willingness to Use Pre-Exposure Prophylaxis in People Who Inject Drugs. <i>Journal of Maine Medical Center</i> , 2021, 3, .	0.1	0
189	Health programmes and services addressing the prevention and management of infectious diseases in people who inject drugs in Canada: a systematic integrative review. <i>BMJ Open</i> , 2021, 11, e047511.	1.9	6
190	Attitudes toward syringe exchange programs in a rural Appalachian community. <i>Journal of Addictive Diseases</i> , 2022, 40, 227-234.	1.3	3
191	Syringe services programs in the Bluegrass: Evidence of population health benefits using Kentucky Medicaid data. <i>Journal of Rural Health</i> , 2022, 38, 620-629.	2.9	1
192	Elucidating Drivers for Variations in the Explosive Human Immunodeficiency Virus Epidemic Among People Who Inject Drugs in Pakistan. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab457.	0.9	0
193	Characterizing opioid-involved overdose risk in local communities: An opioid overdose vulnerability assessment across Indiana, 2017. <i>Preventive Medicine Reports</i> , 2021, 24, 101538.	1.8	5
194	Substance Use: A Social Emergency Medicine Perspective. , 2021, , 157-184.		0
195	Opioid use disorder, infectious diseases, and the criminal justice system. , 2021, , 39-50.		0
196	Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs. , 2016, 2016, .		38
197	Stage-Based Treatment Approaches for Substance Use Disorders. , 2021, , 339-379.		1
198	When is an abscess more than an abscess? Syringe services programs and the harm reduction safety-net: a case report. <i>Harm Reduction Journal</i> , 2020, 17, 34.	3.2	6
199	COVID-19 and People Who Use Drugs - A Commentary. <i>Health Behavior and Policy Review</i> , 2020, 7, 489-497.	0.4	32

#	ARTICLE	IF	CITATIONS
200	The Impact of Methadone Maintenance Treatment on HIV Risk Behaviors among High-Risk Injection Drug Users: A Systematic Review. Evidence-based Medicine & Public Health, 0, 2, .	5.0	36
201	Injection Practices and Sexual Behaviors Among Persons with Diagnosed HIV Infection Who Inject Drugs â€” United States, 2015â€“2017. Morbidity and Mortality Weekly Report, 2019, 68, 653-657.	15.1	17
202	Overdose Education and Naloxone Distribution Within Syringe Service Programs â€” United States, 2019. Morbidity and Mortality Weekly Report, 2020, 69, 1117-1121.	15.1	65
205	Promoting Safe Injection Practices, Substance Use Reduction, Hepatitis C Testing, and Overdose Prevention Among Syringe Service Program Clients Using a Computer-Tailored Intervention: Pilot Randomized Controlled Trial. Journal of Medical Internet Research, 2020, 22, e19703.	4.3	5
206	Computerized Tailored Interventions to Enhance Prevention and Screening for Hepatitis C Virus Among People Who Inject Drugs: Protocol for a Randomized Pilot Study. JMIR Research Protocols, 2016, 5, e15.	1.0	10
207	Preventing blood-borne virus infection in people who inject drugs in the UK: systematic review, stakeholder interviews, psychosocial intervention development and feasibility randomised controlled trial. Health Technology Assessment, 2017, 21, 1-312.	2.8	3
208	Assessing the impact and cost-effectiveness of needle and syringe provision and opioid substitution therapy on hepatitis C transmission among people who inject drugs in the UK: an analysis of pooled data sets and economic modelling. Public Health Research, 2017, 5, 1-118.	1.3	20
209	A qualitative study of injection and sexual risk behavior among unstably housed people who inject drugs in the context of an HIV outbreak in Northeast Massachusetts, 2018. International Journal of Drug Policy, 2021, 95, 103368.	3.3	5
210	PrEP Care Continuum Engagement Among Persons Who Inject Drugs: Rural and Urban Differences in Stigma and Social Infrastructure. AIDS and Behavior, 2022, 26, 1308-1320.	2.7	20
211	Modelling the impact of HIV and HCV prevention and treatment interventions for people who inject drugs in Dar es Salaam, Tanzania. Journal of the International AIDS Society, 2021, 24, e25817.	3.0	5
212	Syringe Services Programsâ€™ Role in Ending the HIV Epidemic in the U.S.: Why We Cannot Do It Without Them. American Journal of Preventive Medicine, 2021, 61, S118-S129.	3.0	39
213	Psychosocial and psychopathological predictors of HIV-risk injecting behavior among drug users in Portugal. Analise Psicologica, 2015, 33, 391-406.	0.2	0
215	Killing More than Pain: Etiology and Remedy for an Opioid Crisis. Current Clinical Psychiatry, 2019, , 1-18.	0.2	0
216	Community pharmacist engagement in HIV and HCV prevention: Current practices and potential for service uptake. Exploratory Research in Clinical and Social Pharmacy, 2021, 4, 100088.	1.0	1
217	Evaluating MontrÃ©alâ€™s harm reduction interventions for people who inject drugs: protocol for observational study and cost-effectiveness analysis. BMJ Open, 2021, 11, e053191.	1.9	1
218	National Needle and Syringe Exchange Program. , 2020, , 201-223.		0
219	Do needle exchange programs decrease the incidence of HIV?. Evidence-Based Practice, 2021, 24, 24-25.	0.0	0
221	Harm-Reduction Interventions. , 2021, , 757-775.		10

#	ARTICLE	IF	CITATIONS
222	Perceptions of Syringe Service Programs and Supervised Use Sites Among a Sample of Registered Voters in a US State. <i>Journal of Public Health Management and Practice</i> , 2021, 27, 361-368.	1.4	2
224	Presenting a conceptual framework for an HIV prevention and care continuum and assessing the feasibility of empirical measurement in Estonia: A case study. <i>PLoS ONE</i> , 2020, 15, e0240224.	2.5	2
225	The Impact of Methadone Maintenance Treatment on HIV Risk Behaviors among High-Risk Injection Drug Users: A Systematic Review. <i>Evidence-based Medicine &amp; Public Health</i> , 2016, 2, .	5.0	43
226	Modeling Combination HCV Prevention among HIV-infected Men Who Have Sex With Men and People Who Inject Drugs. <i>AIDS Reviews</i> , 2017, 19, 97-104.	1.0	4
227	Guide for Future Directions for the Addiction and OUD Treatment Ecosystem. <i>NAM Perspectives</i> , 2021, 2021, .	2.9	0
228	Harm Reduction in Health Care Settings. <i>Medical Clinics of North America</i> , 2022, 106, 201-217.	2.5	10
229	Implementation and first-year operating costs of an academic medical center-based syringe services program. <i>Harm Reduction Journal</i> , 2021, 18, 116.	3.2	2
230	“If You Could Wave a Magic Wand” Treatment Barriers in the Rural Midwest. <i>Substance Abuse: Research and Treatment</i> , 2021, 15, 117822182110533.	0.9	3
231	Applications of research evidence during processes to acquire approvals for syringe services program implementation in rural counties in Kentucky. <i>Annals of Medicine</i> , 2022, 54, 404-412.	3.8	5
232	Perception of Resource Allocations to Address the Opioid Epidemic. <i>Journal of Addiction Medicine</i> , 2022, 16, 563-569.	2.6	3
233	The impact of syringe services program closure on the risk of rebound HIV outbreaks among people who inject drugs. <i>Aids</i> , 2022, Publish Ahead of Print, .	2.2	1
234	Effectiveness of Interventions for Prevention of Common Infections Among Opioid Users: A Systematic Review of Systematic Reviews. <i>Frontiers in Public Health</i> , 2022, 10, 749033.	2.7	10
235	Characteristics of and Experience Among People Who Use Take-Home Naloxone in Skåne County, Sweden. <i>Frontiers in Public Health</i> , 2022, 10, 811001.	2.7	5
236	Optimizing HIV Prevention Efforts to Achieve EHE Incidence Targets. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, 374-380.	2.1	5
237	Modeling the impact of interventions during an outbreak of HIV infection among people who inject drugs in 2012–2013 in Athens, Greece.. <i>Drug and Alcohol Dependence</i> , 2022, 234, 109396.	3.2	2
238	The insanity of addiction treatment in America. <i>Addiction Research and Theory</i> , 0, , 1-6.	1.9	0
239	Structural and community changes during COVID-19 and their effects on overdose precursors among rural people who use drugs: a mixed-methods analysis. <i>Addiction Science &amp; Clinical Practice</i> , 2022, 17, 24.	2.6	15
241	Editorial on “Epidemiology of HIV infection and associated behaviours among people who inject drugs in England, Wales, and Northern Ireland: nearly 40 years on”. <i>HIV Medicine</i> , 2022, 23, 933-935.	2.2	0



#	ARTICLE	IF	CITATIONS
242	Severe bacterial infections in people who inject drugs: the role of injection-related tissue damage. Harm Reduction Journal, 2022, 19, 41.	3.2	11
243	Substance-Related and Addictive Disorders. , 2022, , .		3
244	Factors associated with self-reported avoidance of harm reduction services during the COVID-19 pandemic by people who use drugs in five cities in the United States and Canada. Drug and Alcohol Dependence, 2022, 241, 109544.	3.2	8
245	Urgent need to expand syringe services programs in South Carolina and beyond. Substance Abuse Treatment, Prevention, and Policy, 2022, 17, .	2.2	1
246	Association Between Dual Partnership and Sexual and Injecting Behaviors Among Persons Who Inject Drugs in 23 US Cities, 2018. Archives of Sexual Behavior, 2022, 51, 2667-2678.	1.9	1
247	Long-Acting Injectable Human Immunodeficiency Virus Pre-Exposure Prophylaxis Preferred Over Other Modalities Among People Who Inject Drugs: Findings from a Qualitative Study in California. AIDS Patient Care and STDs, 2022, 36, 254-262.	2.5	8
248	Factors Associated with Exchange Sex Among Cisgender Persons Who Inject Drugs: Women and MSM—23 U.S. Cities, 2018. AIDS and Behavior, 2023, 27, 51-64.	2.7	1
249	Determinants of health among people who use illicit drugs in the conflict-affected countries of Afghanistan, Colombia and Myanmar: a systematic review of epidemiological evidence. Conflict and Health, 2022, 16, .	2.7	2
250	Effect of HCV or HIV infection on mortality among hospitalized persons who used opioids, 2000–2010. Preventive Medicine, 2022, 161, 107155.	3.4	1
251	HIV Transmission Prevention. , 2021, , 30-50.		0
252	Barriers to engaging people who use drugs in harm reduction services during the COVID-19 pandemic: A mixed methods study of syringe services program perspectives. International Journal of Drug Policy, 2022, 109, 103825.	3.3	8
253	Modelling the impact of HIV and hepatitis C virus prevention and treatment interventions among people who inject drugs in Kenya. Aids, 2022, 36, 2191-2201.	2.2	5
254	Use of pre-exposure prophylaxis (PrEP) to prevent rapid HIV transmission among people who inject drugs (PWID) in rural counties in the United States: A modeling study. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, Publish Ahead of Print, .	2.1	0
255	Securing wider EU commitment to the elimination of hepatitis C virus. Liver International, 2023, 43, 276-291.	3.9	7
256	Interventions to prevent HIV and Hepatitis C among people who inject drugs: Latest evidence of effectiveness from a systematic review (2011 to 2020). International Journal of Drug Policy, 2022, 109, 103872.	3.3	13
257	Factors Associated With Severe Bacterial Infections in People Who Inject Drugs: A Single-center Observational Study. Journal of Addiction Medicine, 2023, 17, e202-e205.	2.6	1
258	Nurses and Outreach Workers—Stigmatizing Attitudes in Needle Syringe Programs in Kazakhstan. Research on Social Work Practice, 0, , 104973152211371.	1.9	0
259	Participant perceptions on the acceptability and feasibility of a telemedicine-based HIV PrEP and buprenorphine/naloxone program embedded within syringe services programs: a qualitative descriptive evaluation. Harm Reduction Journal, 2022, 19, .	3.2	1



#	ARTICLE	IF	CITATIONS
260	Evidence of the Impact of Harm Minimization Programs. , 2023, , 1-23.		0
261	The Impact of Needle and Syringe Exchange Programs on HIV-Related Risk Behaviors in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis Examining Individual- Versus Community-Level Effects. AIDS and Behavior, 0, , .	2.7	0
262	Comprehensive needle and syringe program and opioid agonist therapy reduce HIV and hepatitis c virus acquisition among people who inject drugs in different settings: A pooled analysis of emulated trials. Addiction, 2023, 118, 1116-1126.	3.3	3
263	The effects of COVID-19 on New York State’s Drug User Health Hubs and syringe service programs: a qualitative study. Harm Reduction Journal, 2023, 20, .	3.2	2
264	Trends in HIV incidence following scale-up of harm reduction interventions among people who inject drugs in Kachin, Myanmar, 2008–2020: analysis of a retrospective cohort dataset. The Lancet Regional Health - Western Pacific, 2023, 34, 100718.	2.9	3
265	Syringe Services Programs to Reduce Intravenous Disease Transmission in Substance Use Disorders. Nursing Clinics of North America, 2023, , .	1.5	0
266	Are We Witnessing a New Wave of Substance Use Disorders?: A Spotlight on Stimulant Use Disorders. Journal of Psychosocial Nursing and Mental Health Services, 2023, 61, 13-18.	0.6	0
267	Hepatitis C Virus Micro-elimination Among People With HIV in San Diego: Are We on Track?. Open Forum Infectious Diseases, 2023, 10, .	0.9	0
268	Public health interventions, priority populations, and the impact of COVID-19 disruptions on hepatitis C elimination among people who have injected drugs in Montreal (Canada): A modeling study. International Journal of Drug Policy, 2023, 116, 104026.	3.3	0
269	Rationale, evidence, and steps for implementation of medication for opioid use disorder treatment programs in HIV primary care settings. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 0, , 1-8.	1.2	0
270	Substance use disorders: a comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention. World Psychiatry, 2023, 22, 203-229.	10.4	10
271	The impact of syringe decriminalization within the Pennsylvania harm reduction community. Archives of Psychiatric Nursing, 2023, 46, 26-32.	1.4	1
272	People living with <sc>HIV</sc> who inject or have injected nonâ€prescription drugs: Evidence of substantial differences in health inequalities and experiences of clinical care. Drug and Alcohol Review, 2023, 42, 1517-1528.	2.1	1
273	A Case for Needle Exchange Programs: Not Letting Perfection be the Enemy of the Good. Georgetown Medical Review, 2023, 7, .	0.2	0
274	Impact of HCV Testing and Treatment on HCV Transmission Among Men Who Have Sex With Men and Who Inject Drugs in San Francisco: A Modelling Analysis. Journal of Infectious Diseases, 0, , .	4.0	1
275	<sc>HIV</sc> and <sc>HCV</sc> testing at clinical encounters among people who inject drugs, 2013–2018–”Opportunities for increased testing and prevention. Journal of Viral Hepatitis, 2023, 30, 848-858.	2.0	0
276	Mortality associated with bacterial and fungal infections and overdose among people with drug use diagnoses. Annals of Epidemiology, 2023, 87, 45-50.e14.	1.9	0
277	Global associations of key populations with HIV-1 recombinants: a systematic review, global survey, and individual participant data meta-analysis. Frontiers in Public Health, 0, 11, .	2.7	2

#	ARTICLE	IF	CITATIONS
278	“New evidence”™ for Syringe Services Programs? A call for rigor and skepticism. International Journal of Drug Policy, 2023, 121, 104107.	3.3	2
279	HIV risk and prevention among clients of a delivery-based harm reduction service during an HIV outbreak among people who use drugs in northern rural Minnesota, USA. Harm Reduction Journal, 2023, 20, .	3.2	0
280	A mixed methods exploration of injection drug use risk behaviors and place-based norms in Ukraine. , 2023, 154, 209135.		0
281	Elucidating Harm Reduction Principles in a Client-Centered Representative Payee Program. Community Mental Health Journal, 0, , .	2.0	0
282	Needle exchange programs and their impact on HIV incidence in West Virginia: Is it working?. International Journal of Healthcare Management, 0, , 1-12.	2.0	0
283	Unit costs of needle and syringe program provision: a global systematic review and cost extrapolation. Aids, 0, , .	2.2	1
284	A harm reduction journey: Connection, family support, and engagement in health care. , 2023, 155, 209179.		0
285	The Opioid Overdose Epidemic and Response. , 2023, , .		0
286	Evidence of the Impact of Harm Minimization Programs. , 2023, , 415-437.		0
290	Everything but the kitchen sink: An analysis of bacterial and chemical contaminants found in syringe residue from People Who Inject Drugs. Open Forum Infectious Diseases, 0, , .	0.9	0
291	A Qualitative Analysis of Barriers to Accessing HIV Prevention Services During an HIV Outbreak among Persons who Inject Drugs in West Virginia. AIDS and Behavior, 2024, 28, 669-681.	2.7	1
292	Impact of harm minimization interventions on reducing blood-borne infection transmission and some injecting behaviors among people who inject drugs: an overview and evidence gap mapping. Addiction Science & Clinical Practice, 2024, 19, .	2.6	0
293	Statewide efforts to address the opioid epidemic: Results from a national survey of single state agencies. , 2024, 160, 209309.		0
294	An evaluation of first responders’™ intention to refer to post-overdose services following SHIELD training. Harm Reduction Journal, 2024, 21, .	3.2	0
295	“Take services to the people” strategies to optimize uptake of PrEP and harm reduction services among people who inject drugs in Uganda. Addiction Science & Clinical Practice, 2024, 19, .	2.6	0
296	Using cross-species behavioral tools to determine mechanisms contributing to HIV-associated neurocognitive disorder and comorbid substance use. , 2024, , 503-524.		0
297	Kentucky Outreach Service Kiosk (KyOSK) Study protocol: a community-level, controlled quasi-experimental, type 1 hybrid effectiveness study to assess implementation, effectiveness and cost-effectiveness of a community-tailored harm reduction kiosk on HIV, HCV and overdose risk in rural Appalachia. BMJ Open, 2024, 14, e083983.	1.9	0
298	The Intersection of Substance Use Disorders and Infectious Diseases in the Emergency Department. Emergency Medicine Clinics of North America, 2024, 42, 391-413.	1.2	0